Background--Longer QRS duration (QRSd) improves, but increased left ventricular (LV) end-diastolic volume (LVEDV) reduces, efficacy of cardiac resynchronization therapy (CRT). QRSd/LVEDV ratios differ between sexes. We hypothesized that in the EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial enrolling patients with heart failure with QRSd <130 ms, those with larger LVEDV would deteriorate but those with the highest QRSd/LVEDV would improve with CRT.
A ssessment of QRS duration (QRSd) is a key selection criterion for cardiac resynchronization therapy (CRT), recognizing that there is a spectrum of responses. Indications reflect the greatest probability for successful therapy with QRSd >150 ms, less (or no) effect for QRSd <150 ms, and futility (or possible harm) with QRSd <130 ms. 1 However, there is increasing recognition that QRSd may be prolonged not only by reduced myocardial conduction velocity (HisPurkinje lesions) but also by increased left ventricular (LV) dimension acting to extend the "travel distance" of the propagating wavefront. 2 The distinction is important because the former is the target for CRT, but the latter (itself influenced by heart failure [HF] remodeling, sex, and body size/height 3, 4 ) limits CRT response. 5 Hence, any given QRSd reflects the sum effect of factors with opposite implications for CRT success, and this balance may differ among individuals with identical QRSd values. The ratio of QRSd/ LV size may better index CRT substrate. When applied, this was superior to the unadjusted QRSd in predicting successful CRT measured by short-term hemodynamic effects or longterm remodeling among patients with left bundle branch block (LBBB). 3, 6 Patients with a high index score (relatively large
QRSd and small LV size) had higher probability of CRT response compared with those with a low index score (smaller QRS and large LV size) who could worsen with treatment. Interestingly, this calculation explained CRT inefficacy in some patients with LBBB and QRSd >150 ms (ie, meeting class I CRT indications) and conversely why others (principally women) with narrower QRSd (<150 ms) were successfully treated by CRT. These observations raise the intriguing notion that some patients with QRSd <130 ms, together with lower LV dimensions, may also benefit from CRT. We tested this hypothesis post hoc in the EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial, which evaluated CRT effect among patients with QRSd <130 ms and LV dilatation, 7 hypothesizing that patients with larger LV end-diastolic volume (LVEDV) would deteriorate but those with the highest QRSd/LVEDV would improve with CRT. In addition, because among conventionally selected patients undergoing CRT (LBBB and LV ejection fraction [LVEF] <35%), men have greater LV dilation, 3, 6 and numerically a higher all-cause mortality was reported in male patients randomized to CRT-ON in the EchoCRT trial, 8 we assessed interactions of sex with LV size and CRT effect.
Methods Study Design and Conduct
The study was approved by an institutional review board at each participating site, and participants gave written informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The study protocol and main outcome results of the EchoCRT trial were reported previously. 7 In brief, patients with New York Heart Association class III or IV HF with LVEF of ≤35%, optimized medical therapy with QRSd <130 ms and LV enddiastolic diameter ≥55 mm, and echocardiographic evidence of LV dyssynchrony were randomized 1:1 to CRT-OFF (control) or CRT-ON. Device-implanting physicians and physicians involved in the follow-up were aware of the study group assignment, whereas patients, HF physicians, and study personnel completing the follow-up assessments were not. The trial was terminated early after interim analysis because of futility in reaching the primary end point and an observed overall increase in mortality in the CRT-ON group. The current analysis was directed towards assessment of the impact of LV size and QRSd/LV size ratio on the effect of CRT in the EchoCRT trial cohort. QRSd was determined from a standard 12-lead ECG recorded at 25 mm/s before implantation, submitted to the ECG Core Laboratory (University of Glasgow, Glasgow, UK), and echocardiographic data from the Echo Core Laboratory (University of Pittsburgh Medical Center, Pittsburgh, PA). All readers were blinded to the treatment group assignment and any clinical data. Correlations between QRSd, LV size, and height were assessed. LV size was derived from preimplantation biplane LVEDV and indexed to height to account for influence of body size (indexed volumes [mL/m] are reported throughout this article). Then, enrolled patients were dichotomized by median LVEDV value (LVEDV Median ). Because LV size generally is larger in male CRT recipients, 3, 6 and men were the driver for worse outcomes with CRT in the whole EchoCRT trial cohort, 8 we compared CRT effect according to LV size in each sex. We then assessed the quotient QRSd/LVEDV to test the hypothesis that patients with larger QRSd/LVEDV ratios benefited from CRT. Because LV enlargement was a criterion for inclusion (thus restricting the available patient population with
Clinical Perspective
What Is New?
• Although the overall results of the EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial indicated futility or even harm of using cardiac resynchronization therapy in patients with heart failure with QRS duration <130 ms, we discovered that the risk was concentrated among those with larger left ventricular dimensions; conversely patients with longer QRS duration and smaller left ventricular size appeared to benefit from cardiac resynchronization therapy.
What Are the Clinical Implications?
• The assessment of nonelectrical modulators (eg, left ventricular size, sex, and stature) in patients with heart failure may reveal a group with "narrow" QRS duration and smaller ventricles who benefit from cardiac resynchronization therapy.
lower LVEDV), we compared CRT effects in patients stratified in the top quartile (ie, quartile 4 [Q4]; QRSd/LVEDV Q4 ) versus the remainder (ie, quartile 1-quartile 3 [Q1-Q3]; QRSd/ LVEDV Q1-Q3 ). This permitted identification of the subgroup of patients with the least contribution of LV enlargement to QRS prolongation and evaluation of their outcome according to the randomized treatment. Outcomes were assessed by the prespecified primary efficacy outcome (combination of death from any cause and first hospitalization for worsening HF) and secondary outcomes (ie, all hospitalizations for worsening HF throughout the study, all-cause mortality, and cardiovascular mortality). 7 In addition, we measured changes in echocardiographic structural remodeling from baseline to 6 months after implantation. The combination of LVEF increase of ≥5% and LV end-systolic volume decrease of ≥10% was used as a measure of positive CRT effect. 9 Results were compared between sexes.
Statistical Analysis
The study results were analyzed at the independent Statistical Centre at the Robertson Centre for Biostatistics, University of Glasgow. ) were tested for in Cox proportional hazard models. These models included hazard ratios (HRs) with 95% confidence intervals (CIs) that included treatment (CRT-ON and CRT-OFF) adjustments for the following baseline characteristics: sex, country, walking distance, quality-of-life score, sitting systolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use. (The same characteristics, except sex, were used in independent male/female comparisons, followed by 3-way test for interaction.) Time-to-event curves were estimated using the Kaplan-Meier method with the log-rank test. Follow-up was censored at study closure, date of death, LV assist device implantation, heart transplant, withdrawal from the study, or unavailability for follow-up, whichever came first. For structural remodeling analyses, the proportions of patients with events were compared among groups using a v 2 test. Tests for interaction were analyzed using a logistic regression model with CRT randomized treatment and baseline LVEDV grouping included as explanatory variables along with an interaction term. Correlations were reported using the Pearson correlation coefficient.
All tests were 2 sided, with P<0.05 considered to be significant. Table 1 . LV end-diastolic diameter was 11.6% and LVEDV (uncorrected) was 59.4% greater in LVEDV ≥Median versus LVEDV <Median . Patients with LVEDV ≥Median were younger, were more frequently men (%80%) with wider QRSd, had larger body mass index, had less diabetes mellitus, had lower LVEF, and less frequently had underlying ischemic cardiomyopathy. Groups did not differ for dyssynchrony (Table 1) , lead position (Table 2) , or % CRT pacing (97.7AE4.85% versus 97.4AE4.69%; P=0.51).
Results
CRT did not affect any of the measured outcomes in patients with LVEDV <Median (Table 3 ). In contrast, among patients with LVEDV ≥Median , the primary outcome was worsened significantly by CRT ( Figure 1A ) and there were more deaths, both overall (P=0.002) and attributable to cardiovascular causes (P=0.001; significant test for interaction P=0.036) ( Table 3) . When compared, LV structural .3] mL/m; P<0.001). CRT in men with LVEDV <Median(Men) had no effect. In contrast, outcomes were significantly worsened by CRT in LVEDV ≥Median(Men) (Table 4; Figure 1B ). The primary outcome was observed more frequently in this group ( Figure 1B) . Cardiovascular death and number of patients with HF hospitalizations increased significantly (Table 4) 
25}]).
A 3-way test of interaction to test whether sex influenced effects of LVEDV on the relationship between CRT and outcome found no difference between men and women for any of the end points. 
QRSd/LVEDV Ratio and Outcome
The QRS and LV size analysis population included 787 patients with core laboratory electrocardiographic analyses (396 in CRT-OFF and 391 in CRT-ON). Among 621 patients with available echocardiographic data (CRT-ON versus CRT-OFF, n=311 versus n=310), there was a larger proportion demonstrating improvement in LV function with CRT at 6 months after CRT (36.3% versus 27.7%; P=0.022). QRSd/LVEDV ratio in the overall population was a median of 0.99 ms/mL per m (IQR, 0.83-1.19 ms/mL per m). QRSd/LVEDV Q4 patients, when compared with QRSd/ LVEDV Q1-Q3 patients, were older and less tall, with a higher proportion of women, had higher LVEF, and more frequently had underlying ischemic cardiomyopathy, lower body mass index, and more diabetes mellitus (Table 5) . LV enddiastolic diameter was 11.6%, and LVEDV (uncorrected) was 60.5% greater in QRSd/LVEDV Q1-Q3 patients compared with QRSd/LVEDV Q4 patients. There was no difference between groups for dyssynchrony, QRSd, LV lead position (Table 2) , or %CRT pacing (97.5AE4.88% versus 97.6AE4.53%; P=0.87).
After a mean follow-up of 19.4 months, CRT elicited opposite effects in study groups (Table 6, Figure 2) Figure 3A) . Hence, patients in QRSd/LVEDV Q4 gained benefit from CRT.
Effects in each sex were evaluated separately. QRSd/ LVEDV ratio was greater in women (median, 1.1 [IQR, 0.9-1.3] ms/mL) versus men (median, 1.0 [IQR, 0.8-1.2] ms/mL; P<0.001). Among men, primary or secondary outcomes were unaffected by CRT in QRSd/LVEDV Q4 Men but significantly worsened in QRSd/LVEDV Q1-Q3 Men (Table 7) . In women, outcomes were unaffected by CRT in QRSd/LVEDV Q1-Q3 Women or QRSd/LVEDV Q4 Women (Table 7) . A 3-way test of interaction to test whether sex influenced effects of QRSd/ LVEDV on the relationship between CRT and outcome found no difference between men and women for any of the end points. (However, the few female patients in QRSd/LVEDV Q4 [CRT-ON=22; CRT-OFF=24] and paucity of events occurring during the time interval assessed may underpower this comparison.) Echocardiographic data were available in 175 Figure 3B ). However, CRT elicited significant reverse remodeling in QRSd/LVEDV Q4 Women ( Figure 3C ).
Discussion
Among patients with HF with QRSd <130 ms in the EchoCRT trial, those with larger LV dimensions deteriorated with treatment, but in contrast those with larger QRSd and smaller LV size appeared to benefit from CRT. Baseline dyssynchrony did not separate these groups. The QRSd represents the time taken for the electrical wave of myocardial depolarization to move from the His-Purkinje system through the ventricular myocardium. It is prolonged most obviously by HPS delay (eg, LBBB) but also by increased LV dimension, which increases "path length." 2 LV size itself may increase with cardiomyopathy and larger body size. These correlations have been observed in healthy subjects and in patients with cardiomyopathy and LBBB. [10] [11] [12] [13] [14] Among patients with normal QRSd with normal LV function, Stewart et al found that each 10 ms increase in QRSd was associated with a 9.2% increase in LVEDV. 13 Moreover, increase in QRSd was associated with greater height (but not body mass index). We report similar, although modest, correlations in our population with HF with "narrow" QRSd (<130 ms). The correlation of QRSd and LVEDV was 0.32, and the correlation of LVEDV with patient height was 0.30 (thus, reported LVEDV values were normalized for height [mL/m]). No sex differences were observed. However, although a prior study of patients with normal QRSd (but no cardiomyopathy) found no significant sex difference across QRSd when linked to LVEDV and height, 13 here in patients with narrow QRS and HF, we discovered a slight (10%) but significant sex difference in QRSd/LVEDV/height. These interactions are important because any given value of QRSd, the determinant of any individual's candidacy for CRT, represents a composite result of delayed myocardial conduction (ie, the substrate for CRT) but also increased LV size (mass/volume), which may degrade CRT benefit. 5 The ratio of QRSd/LV size was shown recently to be a better predictor of CRT effect than QRSd alone in patients with LBBB, and it differed between sexes and among individuals. 3, 6 Herein, we extended these principles to patients with HF with QRSd <130 ms. First, we tested the impact of LV size, noting that the EchoCRT trial enrolled patients with LV dilatation (assessed by LV diameter). LV volume ranged widely, but QRSd ranged only slightly. We discovered that CRT effect was neutral in those with LVEDV <Median , but it was deleterious in patients with LVEDV ≥Median (Figure 1) . (This observation is consistent with the negative impact of larger LV size on the success of CRT applied for standard indications. 5 )
This may explain our prior result that male patients determined the worse outcomes of CRT-ON for the entire EchoCRT trial cohort 8 : more men were enrolled, and their LV size was larger, but this was not a sex-specific effect, according to our results. Next, we assessed the impact of QRSd/LV size stratified by quartiles. The primary outcome was worsened among patients treated by CRT in those with lower QRSd/LV size, but it was possibly improved in the highest quartile (QRSd/LVEDV Q4 ) ( Figure 2 ) (similar to prior observations in patients with LBBB 3, 6 ). Effects on overall death and on structural remodeling indexes were consistent, with CRT benefit in QRSd/LVEDV Q4 . Notably, although CRT elicited opposite effects in these 2 groups (ie QRSd/LVEDV Q1-Q3 vs QRSd/LVEDV Q4 ), QRSd and echocardiographic dyssynchrony indexes were similar (ie, these were not differentiators). There was a significant sex difference in QRSd/LVEDV ratio: it was greater in women. Despite this favorable substrate, no sex difference between CRT response in QRSd/LVEDV Q1-Q3 and QRSd/LVEDV Q4 was found in multivariable analysis for the primary and secondary outcomes. Although there were proportionally more women in QRSd/LVEDV Q4 , they were still a minority (CRT-ON versus CRT-OFF, 22 versus 24) and experienced few events, underpowering this comparison. Interestingly, improved structural remodeling in QRSd/LVEDV Q4 was largely accounted for by CRT effects in women ( Figure 3 ). The demonstration that some patients with QRS <130 ms may derive benefit from CRT may appear counterintuitive, because CRT aims to reverse delayed LV depolarization, typically LBBB. However, normal QRSd is 85 to 92 ms, and the cut point of 120 ms to select "wide" was arbitrarily defined. 11, [15] [16] [17] Hence, it is conceivable that some patients with QRSd <130 ms may have significant LV conduction delay that may form the substrate for successful CRT. However, simple QRSd cut points failed to separate subgroups with positive response to CRT in the EchoCRT trial, as reported previously. 18 Outcomes of patients with QRSd 120 to 130 ms did not differ from those with QRSd <120 ms. Elsewhere, it is well appreciated that accepted LBBB criteria may be seen with QRSd <130 ms, usually in women with smaller stature, and CRT may be beneficial, an effect attributed to smaller heart size. 11 Inclusion of height (and presumably its effect on LV size) in an individual patient meta-analysis of randomized CRT trials supported CRT benefit for patients of shorter stature and QRS <130 ms. 4 Conversely, a nonresponse rate of >20% persisted among patients undergoing CRT with class I indications (LBBB and QRS >150 ms), minimal comorbidities, and well-sited LV leads, an effect at least partially attributable to excessive LV dilatation. 3 Collectively, these reports may explain why QRSd alone is an incomplete predictor of CRT response. Although this influence of LV size on QRSd is recognized in electrocardiographic guidelines, 2 it has not been included in the electrocardiographic criteria exercised for CRT selection.
Our results have significant implications. There has been recurring interest in transferring the well-established benefits of CRT in patients with HF with a wide QRSd to those with narrow QRSd (<130 ms), who account for most patients with HF. Despite anecdotal experience and initial promise from small studies selecting narrow QRSd patients on the basis of echocardiographic evidence of dyssynchrony, results from subsequent randomized trials have been disappointing. 19 Indeed, the overall results of the EchoCRT trial pointed to futility of CRT. The current study shows that inclusion of LV dimension and height in conjunction with QRSd separated groups who were harmed versus others who may gain benefit. Because the trial required LV dilation for enrollment, male patients (72%) dominated the cohort and determine overall trial results. Under these conditions, the isolation of a minority sustaining a positive effect is all the more striking. Because this group was characterized by smallest LV size, and the trial excluded patients with LV diastolic diameter <55 mm, it likely underrepresents the fraction of patients with HF with QRS <130 ms but high QRSd/LVEDV ratio in the community. 
Strengths and Limitations
Although conducted post hoc, this analysis assessed prespecified end points using prospectively collected data sets, requiring no additional review or imputation. Electrocardiographic and echocardiographic data were adjudicated in core laboratories. Analyses were investigator driven (N.V.) and conducted independently without involvement of the sponsor. However, our conclusions should be interpreted as hypothesis generating, because the trial was prematurely terminated, reducing the statistical power of any subgroup analysis and tests for interactions. QRSd/LVEDV ratio was not a stratification factor at trial entry but LV dilatation was, greatly reducing the number of patients with smaller ventricles and the proportion of female enrollees (ie, our interest groups). We indexed LVEDV to height. Indexing LV volumes to body size has not been consistently followed in CRT studies and may contribute to differing conclusions of efficacy among different studies. 20 Structural remodeling data are restricted to baseline to 6-months postimplantation comparison in 621 patients (ie, 78% of the cohort) and not aligned with outcome measures that were assessed at 19 months. Separating contributions to QRSd into either increased path length (size) or conduction slowing by ratio is an approximate method. HF remodeling is a complex process affecting cardiomyocyte and interstitium. Impulse propagation may be affected by LV dilatation but also at tissue, cellular, and subcellullar levels. Thus fibrosis, scar, and reduced intercellular coupling will affect conduction velocity as well as path length. We can only speculate on mechanisms. LV epicardially paced wave fronts during CRT generally propagate more slowly than normal intrinsic conduction and are negatively inotropic, even in normal myocardium. 21 This action may be exaggerated in dilated LVs without myocardial conduction delay, and risks harm. On the contrary, when myocardial conduction is retarded, the same stimulation in a smaller ventricle may restore electrical synchrony and be clinically beneficial.
Conclusion
In the EchoCRT trial, enrolled patients displayed large heterogeneity in LV size, and the negative effects of CRT were concentrated in men with larger ventricles. Conversely, CRT appeared to be beneficial in a minority with smallest indexed LV volumes. These results add to the growing body of data that QRSd assessment for CRT selection should include attention to the nonelectrical modulating influences of LV size, sex, and stature. 3, 4, 6 The hypothesis that CRT may be beneficial in patients with HF with narrow QRSd and smaller ventricles merits prospective evaluation. . CRT in men (B) produced no effect, but in women (C), a beneficial effect was seen in QRSd/LVEDV Q4Women (test for interaction P=0.02). Three-way test of interaction of sex with effects of QRS/LVEDV on CRT effect for outcomes: death/HF hospitalization, P=0.65; death, P=0.79; HF hospitalization, 0.52; and CVD death, P=0.98. CRT indicates cardiac resynchronization therapy; Q1-3, QRSd/LVEDVQ1-Q3 ; Q4, QRSd/LVEDVQ4; CVD, cardiovascular disease; HF, heart failure; LVEDV, left ventricular enddiastolic volume; and Q, quartile. *Hazard ratio (95% confidence interval) adjusted for country, walking distance, quality of life, sitting diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass grafting, and diuretic use; P value from Wald test.
